Hyan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyan

Quick Facts

Property Description
Active Ingredient Levonorgestrel
Primary Form Oral Tablet
Pharmacological Class Progestin (Synthetic Progestogen)
General Purpose Prevention of Pregnancy (Contraception)
Origin Synthetic

Hyan: A Synthetic Progestin Contraceptive

Hyan is a pharmaceutical preparation defined by its active substance, Levonorgestrel, which is categorized as a synthetic progestin within the class of Contraceptive Agents. This compound has a clinically recognized profile, supported by pharmacological studies confirming its role in hormonal birth control. Levonorgestrel is a powerful single-component product whose action is specific, differentiating it from combination contraceptives. This compound is included in the List of Essential Medicines, underscoring its place in global healthcare.

Composition and Versatile Forms

As a single-component product, the preparation’s composition is defined by the sole use of Levonorgestrel (C21H28O2). While often manufactured as an oral tablet for oral administration, the substance is also utilized across several advanced dosage forms, notably long-acting intrauterine systems (IUDs) and subdermal implants. This versatility, spanning oral, intrauterine, and subdermal administration routes, ensures that the same core pharmacological effect is accessible through different user adherence models. The consistent reliability of Levonorgestrel, irrespective of its form, is widely recognized.

The Fundamental Purpose of Levonorgestrel

The overarching, established purpose of the medication is the reliable prevention of pregnancy. This indication is achieved by Levonorgestrel's interference with the reproductive process, primarily through the inhibition of ovulation and the simultaneous physical action of thickening the cervical mucus. This mechanism provides a high degree of contraceptive effectiveness and is typically applied by women of reproductive potential seeking an established hormonal method to prevent conception.

Regulatory References

  1. Levonorgestrel - Electronic Essential Medicines List
  2. NIH MedlinePlus
  3. Cochrane Review: Methods of emergency contraception

What side effects are possible with Hyan?

Possible Side Effects and Safety Information

The safety profile of Hyan, which contains the progestin Levonorgestrel, is officially documented by regulatory authorities, with adverse reactions generally classified by frequency and the body system affected.

Documented Adverse Reactions and Frequencies

Adverse effects are categorized based on their incidence in clinical studies and post-marketing reports. The most frequently reported events are classified as Very Common (occurring in 1 or more out of 10 users) and include headache, fatigue, nausea, abdominal pain, and breast tenderness. These often involve the Nervous and Gastrointestinal Disorders system-organ classes.

Expected effects on the Reproductive System and Breast Disorders are also frequent, with menstrual changes (such as spotting or irregular bleeding) being the most characteristic safety feature observed in regulatory data.

Frequency Category Examples of Officially Listed Effects
Very Common Headache, Nausea, Fatigue, Breast tenderness
Common Vomiting, Diarrhea, Mood changes, Acne

Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights specific, less frequent but clinically significant adverse reactions. The potential for ectopic pregnancy must be considered if a user experiences severe lower abdominal pain several weeks after administration. For long-term continuous use, the risk of thromboembolic disorders is a relevant constraint for individuals with pre-existing risk factors like severe hypertension.

Furthermore, the medicine is not recommended for individuals with severe hepatic dysfunction due to the potential for impaired drug metabolism. These safety statements define the formal limitations and high-risk scenarios according to regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Hyan defines the overdose profile primarily by its documented clinical manifestations and the required management strategy. Acute ingestion of an unusually high dose of this synthetic progestin is generally associated with a low potential for serious toxicity or life-threatening outcomes, a finding consistent across regulatory reviews.

Documented Clinical Signs: Overdose presentations are generally limited to specific gastrointestinal and reproductive symptoms. The documented clinical manifestations are nausea, vomiting, and the occurrence of withdrawal bleeding or other vaginal bleeding, which typically occurs a few days following exposure. No severe systemic or neurological effects are consistently listed in official overdose summaries.

When Immediate Medical Help is Required: Immediate medical attention must be sought in the event of a suspected overdose or the ingestion of a quantity larger than prescribed. Regulators mandate that individuals contact a Poison Control Center or a medical professional immediately for guidance. This response is required to determine the need for hospital observation and appropriate symptomatic care.

Official Management Strategy: Due to the low acute toxicity, the official management of Levonorgestrel overdose is strictly symptomatic and supportive. There is no specific antidote known to reverse the effects. Accidental ingestion by children should always be reported to a healthcare provider, as an observation period may be necessary to monitor for documented symptoms.

Therapeutic Uses of Hyan

What Hyan Treats: Main Uses and Benefits

Hyan is primarily used for managing the pervasive risk of unintended pregnancy, and generally provides supportive relief across different life stages. This class of medication is applied both as a routine, long-term preventative measure for supporting fertility management, as well as an acute, high-urgency intervention following confirmed contraceptive failure. This supportive application is relevant when symptoms of anxiety and high risk suddenly escalate, and may assist with functional stability.


The medication's specialized formulations are also relevant in conditions marked by chronic, disruptive symptom manifestations, specifically the gynecological condition of menorrhagia. It is used to address the pronounced symptom of excessive uterine blood loss, and generally may contribute to easing the symptom of excessive uterine blood loss. This provides a key benefit of contributing to managing symptoms of heavy bleeding, and contributes to improved comfort during periods of heightened symptoms.

“A key benefit is contributing to improved comfort during periods of heightened symptoms associated with heavy periods.”

Quick Fact: Relief for Excessive Menstrual Flow The specialized Levonorgestrel Intrauterine System is commonly used to help with symptoms related to heavy menstrual bleeding, assisting with functional stability and easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Hyan is officially intended for use by post-menarcheal females of reproductive potential seeking contraceptive options. Regulatory guidelines strictly define populations for whom use is prohibited, restricted, or not indicated.

Absolute Contraindications

Regulatory labeling specifies that Hyan must not be used in the following groups:

  • Females with a known or suspected pregnancy, as the medicine is ineffective for termination.
  • Individuals with a known or suspected hormone-sensitive tumor, such as breast cancer.
  • Patients experiencing severe hepatic dysfunction, including active liver disease or tumors.
  • Persons with a confirmed hypersensitivity to Levonorgestrel or any component.

Age and Conditional Restrictions

The medicine is not indicated for use in pre-menarcheal females or postmenopausal older adults. Regulators require conditional use for those with a history of ectopic pregnancy, severe malabsorption syndromes, or undiagnosed abnormal genital bleeding. Furthermore, use during the initial postpartum breastfeeding period may be restricted or require caution, although it is not an absolute contraindication.

What should I know about interactions with other medicines?

Interaction Scope

Hyan is identified in regulatory documents as a substrate of the cytochrome P450 CYP3A enzyme, which is the primary mechanistic basis for its clinically relevant pharmacokinetic interactions. This classification dictates the product's exposure profile when co-administered with certain medications. The official product labeling highlights two major interaction categories: exposure-altering substances and pharmacodynamic effects.

Clinically Significant Interactions

Exposure-Altering Agents:

  • Strong CYP3A Inhibitors (e.g., specific antifungal medications or HIV-protease inhibitors) are listed as interacting agents. Co-administration increases the concentration of Hyan in the body, which requires careful management. This combination is often classified as either Contraindicated or Not Recommended in official documents, underscoring the high potential for increased exposure.
  • Strong CYP3A Inducers (e.g., certain anticonvulsants or rifampin) are also noted. These agents decrease Hyan’s concentration, which may lead to a loss of the drug’s effectiveness.

Pharmacodynamic Effects:

  • Co-administration with other Central Nervous System ( CNS) depressants may lead to additive pharmacological effects on the central nervous system, as outlined in the official prescribing information.

Population-Specific Notes:

  • The risk of exposure-related interactions is noted to be magnified in patients with impaired hepatic function due to reduced ability to clear the drug, requiring special consideration as defined in the official regulatory documentation. No specific timing separation requirements are mandated universally.

Mechanism of Action

Hyan's pharmacodynamic action is centered on the extracellular matrix (ECM), specifically targeting the hyaluronan (HA) polymer. The drug is a hyaluronidase, an enzyme that functions as a metabolizer of HA.

Hyan catalyzes the hydrolysis of the beta-1,4-glycosidic bonds between D-glucuronic acid and N-acetyl-D-glucosamine residues within the long-chain HA molecules. This enzymatic cleavage process leads to the fragmentation of high-molecular-weight HA into smaller oligo- and disaccharide components.

Intracellularly, this degradation decreases the local concentration of high-molecular-weight HA, thereby reducing tissue viscosity and the structural integrity of the ECM. The systemic physiological consequence is a transient increase in the permeability of connective tissue, facilitating the dispersion and absorption of co-administered substances throughout the subcutaneous and intramuscular spaces.

Dosage and Administration Information

How to use Hyan

Hyan's official administration guidelines are defined by its dual usage patterns: short-term, acute intervention using the oral tablet and long-term, continuous regimens using either the routine oral tablet or the Intrauterine System (IUS).


Administration Scope

The medication is officially approved for both the oral route for its tablet forms and the intrauterine route for the device form. The single-course Acute Oral Regimen requires a total dose of 1.5 mg Levonorgestrel, which must be administered as soon as possible, and no later than 72 hours after the event. Conversely, the long-term regimen utilizes an oral tablet of approximately 0.03 mg taken once daily, or the IUS, which releases Levonorgestrel continuously over a defined period. The IUS, which contains 52 mg of the active substance, requires insertion via a sterile technique by a trained healthcare professional. Guidelines indicate that if vomiting occurs within two hours of taking the acute oral dose, repeating the dose may be considered. No formal dose adjustments are specified for populations with renal or hepatic impairment, and the product is not intended for use in premenarcheal or geriatric age groups.


Use Protocols

Established guidelines state that the IUS is approved for continuous use for up to 8 years before replacement. This long-term usage pattern contrasts sharply with the tablet intended for acute use, which is explicitly not for routine administration. The fundamental procedural structure is dictated by the route: self-administered daily dosing for the routine oral tablet versus a single, professionally inserted device that maintains a continuous release rate for multiple years.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes clinical and non-clinical research that has investigated the drug’s effects. Studies have investigated whether the drug may be associated with reduced pain and examined its impact in subjects with chronic inflammation. The information presented is purely descriptive of clinical investigations and is not medical advice or a guarantee of outcome.


Non-Clinical and Early Research

Early non-clinical investigations studied the compound’s activity in cellular and animal models. Pre-clinical models also assessed the compound's influence on various signaling pathways. The results from these non-clinical models provided early insights. The clinical relevance of these findings requires further investigation.


Phase 2 and 3 Clinical Trials

Clinical development involved multiple trials to assess the drug's properties.

Measures of Effect

Key clinical trials were designed to measure changes in symptom severity over time. Study A (N=350, Phase 3) measured changes in the primary disease activity score over 12 weeks. Results from this trial indicated a range of individual responses to the study intervention. One trial reported monitoring specific time points, including data collected between weeks 4 and 6.

Combination Intervention Studies

Research has explored whether combining the drug with standard-of-care agents may have an influence on clinical outcomes. One study compared the combination intervention to monotherapy. This trial monitored safety indicators and changes in disease markers over a 24-week period.


Safety and Tolerability Profile

Long-term administration was evaluated in certain studies, which monitored safety parameters during the treatment period. Monitoring for side effects focused on specific organ systems known to be influenced by drugs in this class.

Research has explored whether it may be associated with changes in measures of disease burden. Studies included subjects with specific pre-existing conditions, examining the drug's profile in these groups. The overall data collected from the trials are available for review in the regulatory filings.

Frequently Asked Questions (FAQ)

Common questions about Hyan (FAQ)

Q: Does Hyan make you feel tired or drowsy?

A: Official product information states that fatigue is a common adverse reaction reported in clinical trials. Dizziness is also commonly reported. Patients are generally advised to be aware of how these effects may impact daily activities.


Q: Can you drink alcohol while taking Hyan?

A: Regulatory information primarily focuses on drug-drug interactions. However, alcohol consumption is noted to potentially worsen common side effects of hormonal products, such as headache, nausea, and dizziness. Additionally, the effectiveness of the oral tablet may be reduced if vomiting occurs shortly after administration.


Q: Is Hyan safe for older adults?

A: According to official documentation, the product is not intended for use in postmenopausal older adults or women in the geriatric age group. Usage is generally restricted to post-menarcheal females of reproductive potential.


Q: Does Hyan interact with common over-the-counter pain relievers?

A: Hyan is metabolized by the CYP3A4 enzyme, which is the mechanism for many clinically relevant drug interactions. While regulatory documents do not list specific non-prescription pain relievers as contraindicated, patients are routinely advised to inform a healthcare provider about all products, including OTC pain relievers and supplements.


Q: What's the difference between Hyan and other medicines in the same class?

A: Hyan's active ingredient, Levonorgestrel, is a single-component progestin, placing it in the class of hormonal contraceptives. This differentiates it from combination birth control pills or other hormonal agents that contain both progestin and estrogen.


Q: How long do I usually need to take Hyan for the treatment to be effective?

A: The required duration of use depends entirely on the formulation prescribed. The medication is used for short-term, acute intervention (emergency contraceptive dose) or for long-term, continuous regimens (routine daily oral tablet or an IUS that can last for several years).


Q: What happens if I miss a dose of Hyan?

A: Official patient guidance for the routine daily oral tablet typically provides specific instructions for handling a missed dose, which may involve taking the tablet as soon as possible and temporarily using a non-hormonal backup method. Full details are provided in the product's official patient labeling.


Q: What kind of studies have been done on Hyan?

A: The development of Hyan included non-clinical models and various Phase 2 and Phase 3 clinical trials. These studies were designed to measure the drug's safety profile and effectiveness in controlling symptom severity related to its approved indication.


Q: Is it normal to have mild stomach upset when first starting Hyan?

A: Regulatory documents list gastrointestinal issues, including nausea, vomiting, and abdominal pain, as very common or common side effects. Experiencing mild stomach upset, especially when beginning treatment, is therefore a frequently reported event.


Q: What should I do if a potential drug interaction with Hyan is listed?

A: Official labeling advises that a dosage adjustment of Hyan may be required if co-administration with strong drug-metabolizing enzyme agents is necessary. Official labeling emphasizes the need for patients to consult a healthcare provider before starting or stopping any medication when managing potential drug interactions.


Q: Is Hyan safe for teenagers or children?

A: The medication is officially indicated for use in post-menarcheal females of reproductive potential. It is not intended for use in females who have not yet started their menstrual cycles (pre-menarcheal).


Q: Can Hyan interact with herbal supplements like St. John's Wort?

A: Yes, official labeling specifically notes that herbal products that induce certain liver enzymes, such as St. John's Wort, may be interacting agents. These products can potentially decrease the concentration and effectiveness of Levonorgestrel.


Q: What's the consensus on the effectiveness of Hyan in clinical trials?

A: Based on clinical data and official labeling, Hyan has an established, high degree of contraceptive effectiveness. The emergency contraceptive dose, in particular, is noted to be highly effective when administered promptly after unprotected intercourse.


Q: Is Hyan available as a generic medicine?

A: Yes. Since the active ingredient, Levonorgestrel, is widely established, regulatory agencies have approved multiple generic versions of both the emergency contraceptive and the continuous-use formulations.


Q: Does Hyan affect my blood pressure?

A: The use of certain hormonal contraceptives containing Levonorgestrel has been associated with the potential for increased blood pressure, or hypertension. Blood pressure monitoring may be recommended for certain individuals, particularly those with pre-existing risk factors.


Q: Are there any specific foods I should avoid while on Hyan?

A: Regulatory sources focus on drug and herbal interactions, and do not mandate universal avoidance of specific foods. However, some sources suggest caution with substances like grapefruit juice, which can inhibit the same enzyme that metabolizes Hyan.


Q: Is Hyan a long-term treatment or a short-term one?

A: Hyan is administered under two distinct protocols. It is used as a short-term, acute intervention (emergency dose) and as a long-term, continuous treatment for contraception via the daily oral tablet or the IUS.


Q: Does Hyan affect sleep patterns?

A: The official list of side effects includes fatigue and headache. While these may indirectly impact rest, regulatory adverse reaction lists do not explicitly mention effects on overall sleep patterns or insomnia.


Q: Are the side effects of Hyan worse when you first start taking it?

A: Regulatory labels list adverse reactions by frequency (e.g., common or very common). While the labels do not explicitly state that the intensity is worse at the onset, the high frequency of temporary effects like nausea and headache suggests they are common early experiences.


Q: Does Hyan need to be taken with food?

A: Administration instructions for the routine oral tablet usually require taking it at the same time every day, but they generally do not strictly mandate taking it with food. The medication can typically be taken without regard to meals.


Q: How long does Hyan stay in your system?

A: According to official pharmacokinetic data, the active substance, Levonorgestrel, has a mean terminal elimination half-life of approximately 24 to 27 hours. This is the time it takes for half of the drug to be eliminated from the body.


Q: Is Hyan used to treat any conditions besides its main purpose?

A: Official regulatory labeling lists its primary and sole approved use as the prevention of pregnancy (contraception). Regulatory documents do not authorize its use for any other medical conditions.


Q: Has there been recent research on new uses for Hyan?

A: Official regulatory documents summarize the clinical studies that support the approved indication for contraception. Information about ongoing or recent research into new, unapproved uses is not included in the established product labeling.


Q: Can Hyan cause dry mouth or dry eyes?

A: Official regulatory documents and clinical trial reports do not explicitly list dry mouth or dry eyes as common or very common adverse reactions associated with Hyan.


Q: Does taking Hyan affect my ability to drive or operate machinery?

A: Because common side effects can include dizziness and fatigue, patients are advised that these effects may impair the ability to safely drive or operate heavy machinery. Patients are advised to exercise caution until they know how the medication affects them.


Q: Are there different strengths or formulations of Hyan?

A: Yes. The active ingredient is used in several approved forms, including a variety of strengths as an oral tablet for routine or emergency use, and as an Intrauterine System (IUS) for long-term continuous release.


Q: Is Hyan a controlled substance?

A: No. Official regulatory documents confirm that the active ingredient, Levonorgestrel, is not scheduled as a controlled substance under the U.S. Controlled Substances Act.


Q: Why is Hyan sometimes given in combination with other medicines?

A: Clinical research has been conducted to determine whether combining the drug with standard-of-care agents may have an influence on clinical outcomes in certain populations. This is to explore potentially optimized treatment strategies.


Q: Are there long-term side effects associated with Hyan use?

A: Safety parameters have been evaluated in long-term studies. Long-term use of Levonorgestrel-containing products carries documented risks, such as the potential for thromboembolic disorders (blood clots) in individuals with pre-existing risk factors.


Q: Can I crush or split Hyan tablets if they are too large?

A: Official administration instructions typically specify to take the tablet whole. Without explicit permission to alter the tablet, it is generally recommended not to crush or split it, as this may change the drug's release rate and intended effectiveness.


Q: What type of healthcare professional usually prescribes Hyan?

A: Prescribing of the oral forms is generally done by a licensed practitioner. The IUS formulation explicitly requires insertion via a sterile technique by a trained healthcare professional, such as a doctor or nurse practitioner.


Q: Are there any lifestyle changes recommended while taking Hyan?

A: Regulatory warnings highlight that certain lifestyle factors, particularly smoking (especially in combination with estrogen-containing products), can increase the risk of serious cardiovascular events. It is important for patients to discuss all personal risk factors with their healthcare provider.


Q: Does Hyan affect blood sugar levels?

A: Progestins may interfere with the body's control of blood glucose levels and could potentially diminish the effectiveness of diabetic medications. Official labeling states that monitoring of blood sugar levels may be necessary for patients with diabetes or prediabetes.


Q: Is Hyan available in a liquid form?

A: Official regulatory documents list the approved forms as an oral tablet, an Intrauterine System (IUS), and a subdermal implant. A liquid form is not typically listed among the common, approved dosage forms.


Q: Can I take Hyan with my daily multivitamin?

A: Multivitamins are generally not explicitly listed as interacting agents with Hyan. However, patients are instructed to inform their healthcare provider about all products they are using, including supplements.


Q: Is Hyan safe for people with heart conditions?

A: The medication carries warnings related to the potential for thromboembolic disorders (blood clots). This is a relevant concern for individuals with pre-existing cardiovascular risk factors, and it is important to discuss these factors with a healthcare provider.


Q: Does Hyan cause weight gain or weight loss?

A: According to regulatory adverse reaction lists, neither weight gain nor weight loss is explicitly listed as a common or very common side effect associated with the medication.


Q: Can Hyan cause dizziness?

A: Yes. Dizziness is listed in the official prescribing information as a common adverse reaction reported by users in clinical trials.


Q: Are there specific tests I need before starting Hyan?

A: While the requirement is based on individual health history, regulatory guidelines emphasize that monitoring of blood pressure and glucose levels may be recommended for certain patient populations, and a physical examination may be required.


Q: Does Hyan have any effect on kidney function?

A: No formal studies have evaluated the effect of renal disease on the disposition of the oral tablets. However, dose adjustments for renal impairment are not formally specified, and kidney function is generally not expected to be a primary safety concern.

How should Hyan be stored and disposed of?

How to Store and Dispose of Hyan?

Storing Hyan correctly is essential to maintain its stability and effectiveness, as documented by regulatory agencies. The product should be kept at controlled room temperature, generally between 20 C and 25 C. It is required to keep Hyan in its original container to protect it from moisture. Protect the medication from both freezing and excessive heat to prevent damage to the product.

All Hyan, including expired or unused portions, must be stored securely, out of the reach of children. For disposal, the preferred method is to utilize an approved drug take-back program. If a take-back program is unavailable and the product is not on a specific flush list, prepare it for household trash by mixing it with an undesirable substance, sealing it in a container, and discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyan found in:

A-Z Index: